For future clinical translation, if these findings are replicated, schizophrenia-PRS and genotype-predicted CYP2C19 activity may be used in conjunction with nongenetic factors to help predict clozapine response, ultimately allowing early identification of individuals more likely responding to clozapine. This evidence concerns the gene CYP2C19 and schizophrenia.